CRSP:NASDAQ
Crispr Therapeutics AG
$55.43
arrow_downward
-0.02%(-0.0100) 1D
$55.30
arrow_downward
-0.23% (-0.13)bedtimeAfter hours
Closed: Oct 2, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for CRSP...
Open
$56.45
High
$57.58
Low
$54.09
Mkt. cap
5.36B
Avg. vol.
1.60M
Volume
1.13M
52-wk high
$78.48
52-wk low
$44.12
EPS
-$4.76
Beta
1.45
Shares outstanding
96.69M
No. of employees
393
Open
$56.45
High
$57.58
Low
$54.09
Mkt. cap
5.36B
Avg. vol.
1.60M
Volume
1.13M
52-wk high
$78.48
52-wk low
$44.12
EPS
-$4.76
Beta
1.45
Shares outstanding
96.69M
No. of employees
393
News stories
From web sources and news partners
Traders Union
·
23 minutes ago
S&P500 has posted gains in nearly every November-through-June period since 1942, Lia Holmgren notes
TradingView
·
1 hour ago
Getty Images Delists From NYSE, Shares Begin Trading Over The Counter Market
Simply Wall Street
·
1 hour ago
What Was Actually At Stake In Kanzhun's 34% Slide
Profile
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland; Boston, Massachusetts; San Francisco, California; and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts, won the Facilities of the Year Award award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration in December 2023. Wikipedia
About Crispr Therapeutics AG
CEOSamarth Kulkarni
Employees393
Founded2013
HeadquartersZug, Zug, Switzerland
SectorBiotechnology
Websitecrisprtx.com